Es Cushing Glucocorticoid Antagonist Diabetes Glucose Intolerance

---
name: es-cushing-glucocorticoid-antagonist-diabetes-glucose-intolerance
description: This skill suggests administering a glucocorticoid antagonist (e.g., mifepristone) in patients with Cushing's disease who have diabetes or glucose intolerance and are not surgical candidates or have persistent disease after transsphenoidal surgery. Consider when encountering persistent hypercortisolism after TSS, contraindications to surgery, or comorbid diabetes/glucose intolerance requiring medical control.
---

# Glucocorticoid Antagonist in Patients With Diabetes or Glucose Intolerance Who Are Not Surgical Candidates or Have Persistent Disease After TSS

## STEP 1 — Gather Information
Confirm ACTH-dependent Cushing's disease (CD) via biochemical testing (elevated UFC, lack of suppression on dexamethasone). Assess diabetes/glucose intolerance (HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or 2‑h OGTT ≥200 mg/dL). Determine surgical candidacy (review comorbidities, prior TSS outcomes, patient preference). If postoperative, obtain latest serum cortisol or UFC to document persistence.

## STEP 2 — Rule In / Rule Out
Is the patient NOT a surgical candidate OR does the patient have persistent hypercortisolism after TSS? If YES, proceed to Step 3. If NO, consider first‑line surgery or other second‑line options per guideline.

## STEP 3 — Classify or Stratify
Does the patient have diabetes or glucose intolerance? If YES, proceed to Step 4. If NO, consider alternative medical therapy (e.g., steroidogenesis inhibitors) per 6.4a.

## STEP 4 — Decide
Administer a glucocorticoid antagonist (mifepristone). Start at 300 mg daily, titrate upward based on clinical response (glucose, weight, blood pressure) up to 1200 mg/day as needed. Monitor for adrenal insufficiency clinically (fatigue, nausea, hypotension) and avoid relying on cortisol levels for efficacy assessment.

## Clinical Guardrails / Mimics / Pitfalls
Do not use in pregnancy (abortifacient risk). Watch for hypokalemia, hypertension, edema, and endometrial thickening; correct hypokalemia before and during therapy. Do not rely on UFC or serum cortisol to guide dose; efficacy is assessed via glucose, weight, and blood pressure. Avoid in patients with known adrenal insufficiency unless glucocorticoid replacement is planned.

## Concrete Clinical Example
A 48‑year‑old woman with recurrent CD after TSS, HbA1c 8.1%, not a surgical candidate due to severe COPD, started mifepristone 300 mg daily. Titrated to 600 mg daily over 4 weeks; HbA1c improved to 7.0%, weight decreased 4 kg, blood pressure improved, with no signs of adrenal insufficiency.

**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI:10.1210/jc.2015-1818